AR086356A1 - Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2 - Google Patents
Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2Info
- Publication number
- AR086356A1 AR086356A1 ARP120101668A ARP120101668A AR086356A1 AR 086356 A1 AR086356 A1 AR 086356A1 AR P120101668 A ARP120101668 A AR P120101668A AR P120101668 A ARP120101668 A AR P120101668A AR 086356 A1 AR086356 A1 AR 086356A1
- Authority
- AR
- Argentina
- Prior art keywords
- diabetes
- treatment
- type
- pharmaceutical combination
- patients
- Prior art date
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- XVVOERDUTLJJHN-IAEQDCLQSA-N lixisenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 XVVOERDUTLJJHN-IAEQDCLQSA-N 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
La presente se refiere a una combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.Reivindicación 1: Una combinación farmacéutica para su uso en el tratamiento de un paciente que padece diabetes de tipo 2, comprendiendo dicha combinación (a) desPro36Exendin-4(1-39)-Lys6-NH2 y/o una sal de la misma farmacéuticamente aceptable, y (b) metformina y/o una sal de la misma farmacéuticamente aceptable, en la que el compuesto (a) se administra una vez al día antes de una cena.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11166052 | 2011-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR086356A1 true AR086356A1 (es) | 2013-12-04 |
Family
ID=46052773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101668A AR086356A1 (es) | 2011-05-13 | 2012-05-11 | Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20130040878A1 (es) |
| EP (1) | EP2709652A1 (es) |
| JP (1) | JP6005140B2 (es) |
| KR (1) | KR20140041553A (es) |
| CN (2) | CN103648519A (es) |
| AR (1) | AR086356A1 (es) |
| AU (1) | AU2012257780B2 (es) |
| BR (1) | BR112013029256A8 (es) |
| CA (1) | CA2835336A1 (es) |
| MX (1) | MX356728B (es) |
| RU (2) | RU2013155480A (es) |
| WO (1) | WO2012156312A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3228320B1 (de) | 2008-10-17 | 2019-12-18 | Sanofi-Aventis Deutschland GmbH | Kombination von einem insulin und einem glp-1-agonisten |
| AR080669A1 (es) | 2009-11-13 | 2012-05-02 | Sanofi Aventis Deutschland | Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina |
| UY33025A (es) | 2009-11-13 | 2011-06-30 | Sanofi Aventis Deustschland Gmbh | Composicion farmaceutica que comprende un agonista de glp-1 metionina |
| US20110118178A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
| MX339614B (es) | 2010-08-30 | 2016-06-02 | Sanofi - Aventis Deutschland GmbH | Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2. |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| RU2650616C2 (ru) | 2011-08-29 | 2018-04-16 | Санофи-Авентис Дойчланд Гмбх | Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| SG11201504778UA (en) * | 2013-01-17 | 2015-07-30 | Vtv Therapeutics Llc | Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders |
| TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物 |
| RU2016132386A (ru) | 2014-01-09 | 2018-02-14 | Санофи | Стабилизированные фармацевтические составы без глицерина на основе инсулиновых аналогов и/или инсулиновых производных |
| WO2015104314A1 (en) | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| CN114939156A (zh) | 2014-01-09 | 2022-08-26 | 赛诺菲 | 门冬胰岛素的稳定化药物制剂 |
| CN107206058A (zh) | 2014-12-12 | 2017-09-26 | 赛诺菲-安万特德国有限公司 | 甘精胰岛素/利西拉来固定比率配制剂 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| PT2324853E (pt) * | 2009-11-13 | 2015-11-30 | Sanofi Aventis Deutschland | Lixisenatida como adjuvante da metformina no tratamento de diabetes do tipo 2 |
| US20110118178A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
| US20110118180A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
| JP5980466B2 (ja) * | 2009-11-13 | 2016-08-31 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | インスリングラルギン及びメトホルミンへの付加療法を含む２型糖尿病の治療方法 |
-
2012
- 2012-05-10 US US13/468,422 patent/US20130040878A1/en not_active Abandoned
- 2012-05-11 WO PCT/EP2012/058779 patent/WO2012156312A1/en active Application Filing
- 2012-05-11 JP JP2014509759A patent/JP6005140B2/ja not_active Expired - Fee Related
- 2012-05-11 BR BR112013029256A patent/BR112013029256A8/pt not_active Application Discontinuation
- 2012-05-11 AR ARP120101668A patent/AR086356A1/es unknown
- 2012-05-11 KR KR1020137033311A patent/KR20140041553A/ko active Search and Examination
- 2012-05-11 CN CN201280034724.7A patent/CN103648519A/zh active Pending
- 2012-05-11 RU RU2013155480/15A patent/RU2013155480A/ru unknown
- 2012-05-11 MX MX2013013198A patent/MX356728B/es active IP Right Grant
- 2012-05-11 EP EP12720196.0A patent/EP2709652A1/en not_active Withdrawn
- 2012-05-11 AU AU2012257780A patent/AU2012257780B2/en not_active Ceased
- 2012-05-11 CA CA2835336A patent/CA2835336A1/en not_active Abandoned
- 2012-05-11 CN CN201810748089.8A patent/CN109045283A/zh active Pending
- 2012-05-11 RU RU2017129878A patent/RU2017129878A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013029256A2 (pt) | 2016-11-29 |
| CN103648519A (zh) | 2014-03-19 |
| BR112013029256A8 (pt) | 2018-01-16 |
| MX356728B (es) | 2018-06-12 |
| RU2017129878A (ru) | 2019-02-05 |
| CA2835336A1 (en) | 2012-11-22 |
| KR20140041553A (ko) | 2014-04-04 |
| JP2014518860A (ja) | 2014-08-07 |
| EP2709652A1 (en) | 2014-03-26 |
| AU2012257780B2 (en) | 2017-06-01 |
| RU2013155480A (ru) | 2015-06-20 |
| WO2012156312A1 (en) | 2012-11-22 |
| US20130040878A1 (en) | 2013-02-14 |
| CN109045283A (zh) | 2018-12-21 |
| MX2013013198A (es) | 2014-02-20 |
| JP6005140B2 (ja) | 2016-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR086356A1 (es) | Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2 | |
| BR112013019744A2 (pt) | prevenção de hipoglicemia em pacientes com diabetes mellitus tipo 2 | |
| AR081254A1 (es) | Composicion farmaceutica que comprende ave0010 e insulina glargina | |
| CR20140086A (es) | Tratamientos de combinación para hepatitis c | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| CY1119582T1 (el) | Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη | |
| CL2008000198A1 (es) | Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis. | |
| BR112013024973A2 (pt) | prevenção de hipoglicemia em pacientes com diabetes mellitus do tipo 2 | |
| CU20110100A7 (es) | Tratamiento de pirfenidona para pacientes con función hepática atípica | |
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| EA201401028A1 (ru) | Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения | |
| PE20140872A1 (es) | Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple | |
| CY1117603T1 (el) | Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2 | |
| BR112013004756A2 (pt) | uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2 | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| EA200901423A1 (ru) | Бензимидазолы и содержащие их фармацевтические композиции | |
| BR112012016853A2 (pt) | "composições farmacêuticas para administração oral de peptídeos de insulina". | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| CR20110243A (es) | Tratamiento de pirfenidona para pacientes con función hepática. | |
| CY1113755T1 (el) | Η λιξισενατιδη ως επιπροσθετη αγωγη στην ινσουλινη γλαργινη και στη μετφορμινη για τη θεραπευτικη αντιμετωπιση του διαβητη τυπου 2 | |
| CL2012002437A1 (es) | Uso de antiinflamatorio no esteroide (aine) o una sal farmacologicamente aceptable del mismo para preparar un medicamento util para el tratamiento de enfermedades renales cronicas en gatos. | |
| BR112017006272A2 (pt) | composição farmacêutica para tratar colite ulcerativa. | |
| AR103415A1 (es) | Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 | |
| AR086422A1 (es) | Metodo para el tratamiento de tumores solidos avanzados, volasertib | |
| AR084093A1 (es) | Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |